P2Y12 inhibitor

Original Contribution

Contemporary Trends and Outcomes Associated With the Preprocedural Use of Oral P2Y12 Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2)

04/15/2017

Milan Seth , BS, MS;

Hitinder S. Gurm , MBBS, MD, FSCAI;

Devraj Sukul , MD;

Akshay Khandelwal , MD;

Simon R. Dixon , MBChB, FACC, FRACP, MD;

Thomas A. LaLonde , MD;

We sought to describe trends in the use of preprocedural P2Y12 inhibitors and their clinical impact in patients undergoing percutaneous coronary intervention (PCI).

We sought to describe trends in...

04/15/2017

Journal of Invasive Cardiology

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

See Full Calendar

P2Y12 inhibitor

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products